GlassScriptPhysician profile
Syed A Rizvi
NPI 1508837576
$602.06
in general payments reported to CMS, 2019-2025
9 companies · $25.55 in 2025
The $25.55 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.19 · 2020: $48.94 · 2021: $26.90 · 2022: $87.23 · 2023: $149 · 2024: $181 · 2025: $25.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $168.19 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.64 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $70.18 | 2023-2024 | |
| Mylan Specialty L.P. | $69.60 | 2023-2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $56.21 | 2021-2023 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.42 | 2022-2025 | Lifevest |
| Inari Medical, INC. | $36.94 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Gilead Sciences, INC. | $15.81 | 2023 | Veklury |
| Acell, INC. | $14.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.